Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
British Journal of Haematology
|
April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myeloma
Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Blood Cancer Journal
|
August 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Experimental Hematology
|
September 10, 2003
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
Marco Ladetto, Barbara Mantoan, Irene Ricca, et al.
Molecular Cancer Therapeutics
|
June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model
Paola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Blood
|
October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa, Teru Hideshima, Paul Steed, et al.
Breast Cancer Research : BCR
|
April 2, 2024
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications
Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
British Journal of Haematology
|
December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Hiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
British Journal of Haematology
|
April 16, 2008
Fatty acid synthase is a novel therapeutic target in multiple myeloma
Yutaka Okawa, Teru Hideshima, Hiroshi Ikeda, et al.
Blood Cancer Journal
|
August 19, 2024
Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity
Judith Lind, Osman Aksoy, Michaela Prchal-Murphy, et al.
British Journal of Haematology
|
September 20, 2011
The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications
Klaus Podar, Alexander Zimmerhackl, Mariateresa Fulciniti, et al.
Experimental Hematology
|
September 10, 2003
Recurrence of Bcl-2/IgH polymerase chain reaction positivity following a prolonged molecular remission can be unrelated to the original follicular lymphoma clone
Marco Ladetto, Barbara Mantoan, Irene Ricca, et al.
Molecular Cancer Therapeutics
|
June 19, 2007
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe, Teru Hideshima, Laurence Catley, et al.
Journal for Immunotherapy of Cancer
|
May 3, 2024
Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation
Tamara Gassner, Christina Chittilappilly, Theo Pirich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 3, 2007
Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model
Paola Neri, Shaji Kumar, Maria Teresa Fulciniti, et al.
Blood
|
October 25, 2008
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa, Teru Hideshima, Paul Steed, et al.
Breast Cancer Research : BCR
|
April 2, 2024
Correction: Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications
Muhammad Hasan Bashari, Fengjuan Fan, Sonia Vallet, et al.
British Journal of Haematology
|
December 19, 2006
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Hiroshi Yasui, Teru Hideshima, Hiroshi Ikeda, et al.
Page
of 8